Study design: A retrospective study.
Purpose: The aims of this study were to investigate the diagnostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in PET/computed tomography (CT) in the evaluation of spinal metastatic lesions.
Overview of literature: Recent studies described limitations regarding how many lesions with abnormal (18)F-FDG PET findings in the bone show corresponding morphologic abnormalities.
Methods: The subjects for this retrospective study were 227 patients with primary malignant tumors, who were suspected of having spinal metastases. They underwent combined whole-body (18)F-FDG PET/CT scanning for evaluation of known neoplasms in the whole spine. (99m)Tc-methylene diphosphonate bone scan was performed within 2 weeks following PET/CT examinations. The final diagnosis of spinal metastasis was established by histopathological examination regarding bone biopsy or magnetic resonance imaging (MRI) findings, and follow-up MRI, CT and (18)F-FDG PET for extensively wide lesions with subsequent progression.
Results: From a total of 504 spinal lesions in 227 patients, 224 lesions showed discordant image findings. For 122 metastatic lesions with confirmed diagnosis, the sensitivity/specificity of bone scan and FDG PET were 84%/21% and 89%/76%, respectively. In 102 true-positive metastatic lesions, the bone scan depicted predominantly osteosclerotic changes in 36% and osteolytic changes in 19%. In 109 true-positive lesions of FDG PET, osteolytic changes were depicted predominantly in 38% while osteosclerotic changes were portrayed in 15%.
Conclusions: (18)F-FDG PET in PET/CT could be used as a substitute for bone scan in the evaluation of spinal metastasis, especially for patients with spinal osteolytic lesions on CT.
Keywords: 18F-fluorodeoxyglucose positron emission tomography; Metastasis; Positron emission tomography and computed tomography; Spine; Technetium Tc 99m (Sn)methylenediphosphonate.